Deal Library / Pharma BD Deal Intelligence
Pharma Deals of 2024
The Pharma Closeout tracks 391 deals, $160.3B in disclosed deal value, 39 with a post-close Outcome Score for the year 2024.
Median Critic Score: 86 · Median Outcome Score: 65
Best outcome: Nuvation Bio Inc. / AnHeart Therapeutics, Ltd. (100) · Weakest outcome: Ono Pharmaceutical / Shattuck Labs (28)
All 391 deals
- Nuvation Bio Inc. / AnHeart Therapeutics, Ltd. — 2024 · Worked — the deal delivered on its rationale.
- Novo Holdings A/S / Catalent (manufacturing sites) — 2024 · $11.0B · Worked — the deal delivered on its rationale.
- Novartis AG / PTC Therapeutics Inc. — 2024 · $2.9B · Worked — the deal delivered on its rationale.
- Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences — 2024 · $4.9B · Worked — the deal delivered on its rationale.
- Johnson & Johnson / Shockwave Medical — 2024 · $13.1B · Worked — the deal delivered on its rationale.
- Gilead Sciences Inc. / CymaBay Therapeutics — 2024 · $4.4B · Worked — the deal delivered on its rationale.
- AstraZeneca PLC / Amolyt Pharma — 2024 · $1.1B · Largely worked — most objectives met.
- Sarepta Therapeutics Inc. / Arrowhead Pharmaceuticals Inc. — 2024 · $1.1B · Largely worked — most objectives met.
- Novartis AG / PeptiDream Inc. — 2024 · $2.9B · Largely worked — most objectives met.
- H. Lundbeck A/S / Longboard Pharmaceuticals, Inc. — 2024 · $2.6B · Largely worked — most objectives met.
- Novartis AG / Shanghai Argo Biopharmaceutical Co. Ltd. — 2024 · $4.2B · Largely worked — most objectives met.
- Sanofi SA / Inhibrx Inc. — 2024 · $2.2B · Largely worked — most objectives met.
- Harmony Biosciences / Epygenix Therapeutics — 2024 · $680M · Largely worked — most objectives met.
- Ono Pharmaceutical Co., Ltd. / Deciphera Pharmaceuticals — 2024 · $2.4B · Largely worked — most objectives met.
- Biogen Inc. / Human Immunology Biosciences — 2024 · $1.1B · Largely worked — most objectives met.
- Novartis / Arvinas, Inc. — 2024 · $1.2B · Largely worked — most objectives met.
- Bristol-Myers Squibb Company / Prime Medicine Inc. — 2024 · $3.5B · Largely worked — most objectives met.
- Gilead Sciences, Inc. / Xilio Therapeutics, Inc. — 2024 · $544M · Largely worked — most objectives met.
- Johnson & Johnson / Proteologix Inc. — 2024 · $850M · Largely worked — most objectives met.
- Merck & Co. Inc. / Harpoon Therapeutics — 2024 · $680M · Largely worked — most objectives met.
- Bristol-Myers Squibb Company / BioArctic AB — 2024 · $1.4B · Largely worked — most objectives met.
- Merck Sharp & Dohme LLC / Harpoon Therapeutics, Inc. — 2024 · $680M · Largely worked — most objectives met.
- AstraZeneca PLC / Fusion Pharmaceuticals Inc. — 2024 · $2.4B · Largely worked — most objectives met.
- Genmab A/S / ProfoundBio Inc. — 2024 · $1.8B · Largely worked — most objectives met.
- AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2024 · $2.0B · Largely worked — most objectives met.
- Eli Lilly and Company / Morphic Holdings — 2024 · $3.2B · Largely worked — most objectives met.
- GSK plc / Duality Biologics (Suzhou) Co. Ltd. — 2024 · $975M · Largely worked — most objectives met.
- Merck & Co. Inc. / EyeBio Ltd. — 2024 · $3.0B · Largely worked — most objectives met.
- AbbVie Inc. / MedinCell S.A. — 2024 · $1.9B · Largely worked — most objectives met.
- Roche Holding AG / Poseida Therapeutics — 2024 · $1.5B · Largely worked — most objectives met.
- Novartis AG / Voyager Therapeutics Inc. — 2024 · $1.3B · Largely worked — most objectives met.
- GSK plc / Aiolos Bio — 2024 · $1.0B · Largely worked — most objectives met.
- AbbVie Inc. / EvolveImmune Therapeutics Inc. — 2024 · $1.5B · Mixed — partial payoff, real shortfalls.
- Johnson & Johnson / Ambrx Biopharma Inc. — 2024 · $2.0B · Mixed — partial payoff, real shortfalls.
- AbbVie Inc. / Aliada Therapeutics — 2024 · $1.4B · Mixed — partial payoff, real shortfalls.
- Sanofi SA / Novavax Inc. — 2024 · $1.2B · Mixed — partial payoff, real shortfalls.
- Merck & Co. Inc. / Modifi Biosciences — 2024 · $1.3B · Mixed — partial payoff, real shortfalls.
- Novartis AG / MorphoSys AG — 2024 · $2.9B · Underwhelmed — fell short of the thesis.
- Ono Pharmaceutical / Shattuck Labs — 2024 · $227M · Did not work — the deal failed to deliver.
- Tonix Pharmaceuticals / Bilthoven Biologicals — 2024
- Bespin Subsidiary, LLC / Landos Biopharma Inc. — 2024
- Théa Open Innovation SAS / Kiora Pharmaceuticals, Inc. — 2024
- Servier / Aitia — 2024
- ALK-Abelló / ARS Pharma — 2024 · $465M
- Illumina / Fluent Biosciences — 2024
- Fusion Pharmaceuticals / Heidelberg University — 2024
- Xentria / New York University — 2024
- Akari Therapeutics Plc / Peak Bio, Inc. — 2024
- Novartis / Isomorphic Labs — 2024
- Acino International AG / Allecra Therapeutics — 2024
- Merck & Co. Inc. / LaNova Medicines Ltd. — 2024 · $3.3B
- Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc. — 2024 · $1.9B
- Ipsen / Sutro Biopharma — 2024 · $900M
- Apotex / Searchlight Pharma — 2024
- Quest Diagnostics / LifeLabs — 2024 · $985M
- Sato / Arcutis — 2024
- Ginkgo Bioworks / Patch Biosciences — 2024
- Sanofi SA / Belharra Therapeutics, Inc. — 2024 · $700M
- Myriad Genetics / Intermountain Precision Genomics — 2024
- Psyence Biomed / PsyLabs — 2024 · $1M
- Roche Holding AG / Ascidian Therapeutics, Inc. — 2024 · $1.8B
- MSD / Evaxion Biotech A/S — 2024
- TuHURA Biosciences, Inc. / Kineta, Inc. — 2024
- Eli Lilly and Company / QIAGEN — 2024
- Ono Pharmaceutical Co., Ltd. / Monash University — 2024
- Grünenthal / Valinor Pharma — 2024
- SIGA / Vanderbilt University — 2024
- AbbVie / OSE Immunotherapeutics — 2024
- Tenacia Biotechnology / Praxis Precision Medicines — 2024
- Reneo Pharmaceuticals, Inc. / OnKure, Inc. — 2024
- Autonomix / RF Innovations, Inc. — 2024
- Be Biopharma / MaxCyte — 2024
- Immunome Inc. / Zentalis Pharmaceuticals, Inc. — 2024
- Dechra Pharmaceuticals / Invetx — 2024 · $520M
- Astellas Pharma Inc. / Kelonia Therapeutics — 2024
- Nordson Corporation / Atrion Corporation — 2024
- Renalys Pharma / Travere Therapeutics — 2024
- Organon & Co. / Dermavant Sciences Ltd. — 2024 · $1.2B
- MThera Pharma Co., Ltd. / NeuroBo Pharmaceuticals, Inc. — 2024
- GSK / Genomics plc — 2024
- GSK / Vesalius Therapeutics — 2024
- Avalo Therapeutics, Inc. / AlmataBio, Inc. — 2024
- Proliant Health and Biologicals / Dyadic International, Inc. — 2024
- Pepper Bio / G1 Therapeutics — 2024
- M8 Pharmaceuticals / Supernus — 2024
- EQT / Mabtech — 2024
- Laurus Labs / Willow — 2024
- Solid Biosciences / Armatus Bio — 2024
- Bayer AG / Thermo Fisher Scientific Inc. — 2024
- XyloCor / SmartCella — 2024
- AstraZeneca / Allorion Therapeutics — 2024
- AbbVie / Nimble Therapeutics — 2024 · $200M
- Mainz Biomed / Thermo Fisher Scientific — 2024
- Pieris Pharmaceuticals, Inc. / Palvella Therapeutics, Inc. — 2024
- Boehringer Ingelheim / Brainomix — 2024
- Clearmind Medicine Inc. / BIRAD — 2024
- Novo Nordisk A/S / Neomorph Inc. — 2024 · $1.5B
- Astellas / Sangamo Therapeutics — 2024
- Evergreen Theragnostics / Medical University of Innsbruck — 2024
- Servier / AmoyDx — 2024
- Eli Lilly and Company / Radionetics Oncology Inc. — 2024 · $1.1B
- Tome Biosciences / Replace Therapeutics — 2024 · $185M
- Ligand Pharmaceuticals Incorporated / APEIRON Biologics AG — 2024 · $100M
- Boyang Trading / Lifesprout — 2024
- MSD / Orion — 2024
- Polyrizon Ltd. / SciSparc Ltd. — 2024 · $3M
- Novartis AG / Mariana Oncology Inc. — 2024 · $1.8B
- Novartis / Vyriad — 2024
- Astellas Pharma Inc. / Poseida Therapeutics Inc. — 2024 · $550M
- Spyre Therapeutics, Inc. / Paragon Therapeutics, Inc. — 2024
- RAPT Therapeutics / Shanghai Jemincare Pharmaceutical — 2024
- CSL / Genezen — 2024
- Rhythm Pharmaceuticals, Inc. / LG Chem, Ltd. — 2024
- RTI Surgical / Cook Biotech — 2024
- ANI Pharmaceuticals, Inc. / Alimera Sciences, Inc. — 2024 · $381M
- MycoMedica Life Sciences / Enveric Biosciences, Inc. — 2024
- AptarGroup, Inc. / Enteris Biopharma, Inc. — 2024
- Pfizer Inc. / Triana Biomedicines Inc. — 2024 · $1.5B
- 4DMT / Arbor Biotechnologies — 2024
- Elevation Oncology / Synaffix — 2024 · $368M
- Ocean Biomedical / Molecure — 2024
- Roche / MOMA Therapeutics — 2024
- Boehringer Ingelheim / Mary Tyler Moore Vision Initiative — 2024
- Singapore Institute of Advanced Medicine Holdings / EnGeneIC Limited — 2024
- Calibre Scientific / DCS — 2024
- Hercules CM NewCo Inc. (Kailera Therapeutics) / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2024 · $6.0B
- Wugen / MaxCyte — 2024
- Novo Nordisk A/S / NanoVation Therapeutics, Inc. — 2024 · $600M
- Oruka Therapeutics / ARCA biopharma — 2024
- Janssen Biotech / Elektrofi — 2024
- Vetbiolix / Can-Fite — 2024
- Eton Pharmaceuticals, Inc / Ipsen — 2024
- AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2024 · $2.0B
- Menarini Group / Insilico Medicine — 2024
- Cristália / Formosa Pharmaceuticals — 2024
- Alcanza / Kansas City Research Institute — 2024
- AVROBIO, Inc. / Tectonic Therapeutic, Inc. — 2024
- Astellas Pharma Inc. / UMass Chan Medical School — 2024
- Cara Therapeutics, Inc. / Tvardi Therapeutics, Inc. — 2024
- BioNTech / Biotheus — 2024
- Allogene Therapeutics / Arbor Biotechnologies — 2024
- Novartis / Schrödinger — 2024
- Swixx Biopharma / Biopas — 2024
- Kuva / Lisata Therapeutics, Inc. — 2024
- Bayer AG / Google Cloud — 2024
- Harmonic Discovery / BioVentures — 2024
- HanAll Biopharma / Turn Biotechnologies — 2024
- Sanofi / Fulcrum Therapeutics, Inc. — 2024
- Certa Therapeutics / OccuRx — 2024
- Kyowa Kirin / BridgeBio Pharma — 2024
- Oncodesign Services / Zobio — 2024
- Phebra PTY Ltd. / Medsenic — 2024
- Beckman Coulter Diagnostics / ALZpath — 2024
- Serum Institute of India / Valneva SE — 2024
- Ampersand Biomedicines / AbCheck — 2024
- Myriad Genetics / Personalis — 2024
- Telix Pharmaceuticals / QSAM Biosciences — 2024
- MEDIROM Healthcare Technologies / Japan Gene Medicine Corporation — 2024
- Immedica Pharma / Marinus Pharmaceuticals — 2024
- BioNTech / Medilink Therapeutics — 2024
- ReShape Lifesciences Inc. / Vyome Therapeutics, Inc. — 2024
- Eterna Therapeutics Inc. / Factor Bioscience Limited — 2024
- Aerovate Therapeutics / Jade Biosciences — 2024
- HilleVax / Kangh — 2024
- Insud Pharma / Agile Therapeutics, Inc. — 2024 · $45M
- Johnson & Johnson / Numab Therapeutics AG (Yellow Jersey Therapeutics) — 2024 · $1.2B
- Takeda Pharmaceutical Company Ltd. / Degron Therapeutics Ltd. — 2024 · $1.2B
- Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.3B
- Intas Pharmaceuticals Ltd. / Coherus BioSciences, Inc. — 2024 · $558M
- Bayer AG / Samsung Electronics America, Inc. — 2024
- Ferrer Internacional S.A. / Verge Genomics — 2024 · $122M
- Virtual Therapeutics Corporation / Akili, Inc. — 2024
- First Wave BioPharma, Inc. / ImmunogenX, Inc. — 2024
- Omni Bioceutical Innovations Inc. / Kane Biotech — 2024
- Eliem Therapeutics / Tenet Medicines — 2024
- Ginkgo Bioworks / Reverie Labs — 2024
- Alcami / Pacific Pharmaceutical Services — 2024
- Conduit Pharmaceuticals / AstraZeneca — 2024
- Rigel Pharmaceuticals, Inc. / Blueprint Medicines Corporation — 2024 · $15M
- Hasten Biopharmaceutical / Celltrion — 2024
- Merit Medical / EndoGastric Solutions, Inc. — 2024 · $105M
- Pfizer Inc. / UT Southwestern Medical Center — 2024
- Nippon Shinyaku / Atsena Therapeutics — 2024
- Erasca, Inc. / Guangzhou Joyo Pharmatech Co., Ltd. — 2024
- IMCD Spain / Cobapharma — 2024
- WY Biotech / HCW Biologics — 2024
- Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. — 2024 · $850M
- Astellas Pharma Inc. / AviadoBio Ltd. — 2024 · $2.2B
- EpiVario / Metabomed LTD — 2024
- Ipsen / Foreseen Biotechnology — 2024 · $1.0B
- Bayer AG / Aignostics GmbH — 2024
- CoreRx, Inc. / Societal CDMO — 2024
- Double Point Ventures LLC / Lumos Pharma, Inc. — 2024 · $38M
- Rani Therapeutics Holdings, Inc. / ProGen Co., Ltd. — 2024
- Ono Pharmaceutical Co., Ltd. / Congruence Therapeutics — 2024
- Henlius / Sermonix — 2024
- Takeda / Kumquat Biosciences — 2024
- MSD / Mestag Therapeutics — 2024 · $1.9B
- Pharus Diagnostics / City of Hope — 2024
- Brii Biosciences / VBI Vaccines Inc. — 2024 · $33M
- HiRO / DeltaMed Solutions — 2024
- XOMA Corporation / Daré Bioscience, Inc. — 2024 · $22M
- electroCore, Inc. / NeuroMetrix, Inc. — 2024
- IDEAYA Biosciences / Biocytogen — 2024
- Bayer AG / MOMA Therapeutics, Inc. — 2024
- Novartis / IFM Due — 2024 · $835M
- Wheeler Bio / ATUM — 2024
- Ipsen / Biomunex — 2024 · $610M
- Edwards Lifesciences / JenaValve Technology, Inc. — 2024
- Anocca AB / EmendoBio Inc. — 2024
- Novo Nordisk / Cardior Pharmaceuticals — 2024
- Takeda Pharmaceutical Company Ltd. / AC Immune SA — 2024 · $2.2B
- AbbVie Inc. / Celsius Therapeutics Inc. — 2024 · $250M
- Imugene / MaxCyte — 2024
- IDEAYA Biosciences / Hengrui Pharma — 2024 · $1.0B
- Novo Nordisk A/S / Cellarity, Inc. — 2024 · $532M
- Neutrolis / University of Illinois Chicago — 2024
- Ono Pharmaceutical Co., Ltd. / LigaChem Biosciences, Inc. — 2024 · $700M
- Norgine / Fennec Pharmaceuticals — 2024
- STADA Arzneimittel AG / Alvotech — 2024
- BioNTech SE / Biotheus Inc. (Pumai Biotechnology) — 2024 · $950M
- Bluejay Therapeutics, Inc. / Exicure, Inc. — 2024
- Certara / Chemaxon — 2024
- HK inno.N Corporation / Sciwind Biosciences — 2024
- Repligen / Tantti — 2024
- GSK plc / CureVac N.V. — 2024 · $1.6B
- Xylyx Bio / Vanderbilt University — 2024
- Ipsen / Day One — 2024
- XOMA Corporation / Kinnate Biopharma Inc. — 2024
- Theratechnologies / Ionis — 2024
- Avextra AG / SynQube GmbH — 2024
- Neuronetics, Inc. / Greenbrook TMS — 2024
- AlloVir / Kalaris Therapeutics — 2024
- Bristol Myers Squibb / Prothena Corporation plc — 2024
- KARL STORZ / Asensus Surgical — 2024
- Novartis / BioAge Labs — 2024
- Knight Therapeutics / Amneal Pharmaceuticals — 2024
- eMed / Science 37 — 2024 · $38M
- OraSure Technologies / Sherlock Biosciences — 2024
- MannKind Corporation / Pulmatrix — 2024
- Trinity Biotech / EpiCapture — 2024
- Ginkgo Bioworks / Modulus Therapeutics — 2024
- UroGen Pharma Ltd. / medac — 2024
- Otsuka Pharmaceutical Co., Ltd. / iBio, Inc. — 2024
- Ono Pharmaceutical Co., Ltd. / PRISM BioLab — 2024
- GlycoMimetics, Inc. / Crescent Biopharma, Inc. — 2024
- Ensho Therapeutics, Inc. / EA Pharma Co., Ltd. — 2024
- ANEW MEDICAL, INC. / Transfertech Sherbrooke — 2024
- Lyell Immunopharma, Inc. / ImmPACT Bio USA Inc. — 2024
- Ipsen S.A. / Marengo Therapeutics, Inc. — 2024 · $1.2B
- Aclaris Therapeutics / Biosion, Inc. — 2024
- Pharma 1 Drug Store L.L.C / Evofem Biosciences, Inc. — 2024
- Dr. Reddy's Laboratories / Pharmazz, Inc. — 2024
- Instil Bio / ImmuneOnco — 2024
- Lyell Immunopharma / ImmPACT Bio — 2024
- General Inception / Enable Medicine — 2024
- Vignette Bio / EpimAb Biotherapeutics — 2024
- Roche / Remix Therapeutics — 2024
- Roche / Flare Therapeutics — 2024
- AstraZeneca / Achilles Therapeutics — 2024 · $12M
- Immutep Limited / Cardiff University — 2024
- Roche / Codexis — 2024
- Inmagene / HUTCHMED — 2024
- Valneva / LimmaTech — 2024
- Asahi Kasei Corporation / Calliditas Therapeutics AB — 2024
- Chroma Medicine / Whitehead Institute — 2024
- Perspective Therapeutics / Mayo Clinic — 2024
- Angelini Pharma / Cureverse — 2024
- Telix / IsoTherapeutics — 2024
- Merck KGaA, Darmstadt, Germany / C4 Therapeutics, Inc. — 2024
- Space Finco, Inc. / Avid Bioservices, Inc. — 2024 · $1.1B
- Sun Pharma / Taro — 2024
- Almirall, S.A. / Eloxx Pharmaceuticals, Inc. — 2024
- Lantheus Holdings, Inc. / Life Molecular Imaging Ltd. — 2024
- Vitrolife AB (publ) / eFertility — 2024
- I-MED Pharma Inc. / Kane Biotech Inc. — 2024
- Octane Medical Group / B. Braun Melsungen AG — 2024
- Avenzo Therapeutics / Allorion Therapeutics — 2024
- Roche / Medilink Therapeutics — 2024
- Bayer / BridgeBio Pharma — 2024
- Servier / Klineo — 2024
- DÁVI Farmacêutica / Formosa Pharmaceuticals — 2024
- Tetra Pharm Technologies / Glysious — 2024
- Tabuk Pharmaceuticals / Formosa Pharmaceuticals — 2024
- 60 Degrees Pharmaceuticals, Inc. / Tufts Medical Center — 2024
- Kaken Pharmaceutical / Numab Therapeutics — 2024
- SPC Korea / Lipocine Inc. — 2024
- Arbor Biotechnologies / Serendipity — 2024
- Novo Nordisk A/S / Biosplice Therapeutics, Inc. — 2024
- Eisai Co., Ltd. / SEED Therapeutics Inc. — 2024 · $1.5B
- Helix BioPharma / Laevoroc Chemotherapy AG — 2024
- Calibre Scientific / RUWAG — 2024
- VERAXA Biotech / Cherry Biolabs — 2024
- Shenzhen Beimei Pharmaceutical Co. Ltd / Sol-Gel Technologies, Ltd. — 2024
- Royalty Pharma / ImmuNext, Inc. — 2024 · $525M
- Regeneron Pharmaceuticals, Inc. / 2seventy bio, Inc. — 2024
- Flat Medical / InjeQ — 2024
- Akoya Biosciences / NeraCare — 2024
- Celularity / Sequence LifeScience, Inc. — 2024
- Calibre Scientific / MoBiTec — 2024
- Collegium / Ironshore Therapeutics — 2024 · $525M
- Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC — 2024
- XOMA Royalty / Pulmokine — 2024 · $20M
- Emboline / SWAT Medical AB — 2024
- Novartis / Ratio Therapeutics — 2024
- Novo Nordisk A/S / Metaphore Biotechnologies, Inc. — 2024 · $600M
- Essential Pharma / Teva — 2024
- Glioblastoma Foundation, Inc. / Basilea Pharmaceutica Ltd — 2024
- NLS Pharmaceutics Ltd. / Kadimastem Ltd. — 2024
- Galapagos / Adaptimmune — 2024
- Immunome Inc. / Ayala Pharmaceuticals, Inc. — 2024
- Immunome / Nectin Therapeutics — 2024
- Htl Biotechnology / Modern Meadow — 2024
- AbbVie / Umoja Biopharma — 2024
- Eyenovia / SGN Nanopharma — 2024
- Eli Lilly and Company / HAYA Therapeutics SA — 2024 · $1.0B
- Novo Nordisk / Ascendis Pharma — 2024
- Atlas Neon Parent, Inc. / NGM Biopharmaceuticals, Inc — 2024
- Boston Scientific / Axonics, Inc. — 2024
- BiomX Inc. / Adaptive Phage Therapeutics, Inc. — 2024
- Stryker / Vertos Medical, Inc. — 2024
- Monopar Therapeutics Inc. / NorthStar Medical Radioisotopes, LLC — 2024
- Royalty Pharma / Geron — 2024 · $125M
- Boehringer Ingelheim / 3T Biosciences — 2024
- Lee’s Pharmaceutical (HK) Ltd. / Windtree Therapeutics, Inc. — 2024
- Essential Pharma / Renaissance Pharma Ltd — 2024
- Nobelpharma / Y-mAbs — 2024
- Chugai Pharma Europe Ltd. / Helsinn Group — 2024
- AstraZeneca AB / Insmed Incorporated — 2024
- Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc. — 2024 · $1.1B
- Pentixapharm / Glycotope GmbH — 2024
- Adcendo ApS / Duality Biologics — 2024
- Ayrmid Ltd. / BioLineRx, Ltd. — 2024
- Ginkgo Bioworks / Proof Diagnostics — 2024
- Novartis / Deciphex — 2024
- Ipsen Pharma SAS / Sutro Biopharma, Inc. — 2024
- GSK / Rgenta Therapeutics — 2024
- iRhythm Technologies, Inc. / BioIntelliSense, Inc. — 2024
- Recordati S.p.A. / Sanofi SA — 2024 · $1.1B
- Legend Biotech / MaxCyte — 2024
- SPIMA Therapeutics / SATT AxLR — 2024
- Incyte Corporation / Escient Pharmaceuticals Inc. — 2024 · $750M
- Aardvark Therapeutics, Inc. / MEI Pharma, Inc. — 2024
- Veterinary Pharmaceutical Solutions / Diamond Animal Health — 2024
- EVerZom / Erganeo — 2024
- Sionna Therapeutics / AbbVie — 2024
- Ocuphire Pharma / Opus Genetics — 2024
- Relay Therapeutics / Pfizer Inc. — 2024
- Nika Pharmaceuticals, Inc. / Nika BioTechnology, Inc. — 2024
- Bayer Consumer Care AG / Cytokinetics, Incorporated — 2024
- Bridge to Life / Medica S.p.A. — 2024
- Boehringer Ingelheim / Circle Pharma — 2024 · $607M
- Bayer AG / Dewpoint Therapeutics Inc. — 2024 · $424M
- GEMMA Biotherapeutics / Passage Bio — 2024
- Attivare / Wyss Institute — 2024
- Pharmacosmos A/S / G1 Therapeutics, Inc. — 2024
- AbbVie Inc. / Landos Biopharma Inc. — 2024 · $212M
- Partner Therapeutics / Merus — 2024
- Boston Scientific / Silk Road Medical — 2024 · $1.3B
- ONWARD Medical / CEA — 2024
- Sino Biological / SignalChem Biotech — 2024 · $48M
- Akos Biosciences, Inc. / Aries Science and Technology, LLC — 2024
- TG Therapeutics / Precision BioSciences — 2024
- Alkem Laboratories Limited / Sonnet BioTherapeutics Holdings, Inc. — 2024
- Exact Sciences / TwinStrand Biosciences — 2024
- Avenzo Therapeutics Inc. / VelaVigo Bio Inc. — 2024 · $800M
- Ipsen / Skyhawk Therapeutics — 2024 · $1.8B
- Kyowa Kirin Co. Ltd. / Kura Oncology Inc. — 2024 · $1.5B
- Astellas Pharma Inc. / Mass General Brigham — 2024
- AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.7B
- Takeda / Keros Therapeutics — 2024
- Deimos Biosciences / G1 Therapeutics — 2024
- Nippon Shinyaku / Vicore Pharma Holding AB — 2024
- Genentech / COUR Pharmaceuticals — 2024
- Kye Pharmaceuticals / Catalyst Pharmaceuticals — 2024
- Novartis / SanReno Therapeutics — 2024
- Alcanza / Fdi Clinical Research — 2024
- AbbVie / Gedeon Richter — 2024
- Biogen Inc. / Neomorph Inc. — 2024 · $1.4B
- Dr. Reddy’s / Alvotech — 2024
- BridgeBio / Unnatural Products — 2024
- AstraZeneca / Nona Biosciences — 2024
- Trinity Biotech / Metabolomics Diagnostics — 2024 · $1M
- Kamau Therapeutics / MaxCyte — 2024
- Italfarmaco S.p.A. / Iktos — 2024
- Bayer AG / NextRNA Therapeutics, Inc. — 2024 · $547M
- M8 Pharmaceuticals / SERB Pharmaceuticals — 2024
- The Column Group / NGM Biopharmaceuticals — 2024
- Orion / Abilita Therapeutics — 2024
- Thermo Fisher Scientific / Akoya Biosciences — 2024
- Molecular Designs / Lamda Biotech — 2024
← Deal Library ·
Interactive search ·
How we score deals